News and Announcements
Frost & Sullivan Identifies Proteomics International Laboratories as World-Leader in Predictive Diagnostics for Diabetic Kidney Disease
- Published March 27, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Proteomics International Laboratories Ltd (ASX:PIQ) (PILL) is the leader in predictive diagnostics diabetic kidney disease according to a Frost & Sullivan independent report released this month. PILL managing director Dr Richard Lipscombe will be showcasing PromarkerD at the China-Australia Biotech Investment forum in Shanghai today.
KEY TAKEAWAYS:
- The respected research house goes on to highlight PILL’s novel test for diabetic kidney disease, called PromarkerD, nothing its “high adoption potential”.
- This follows news that the PromarkerD technology has been validated by the peer-reviewed scientific journal EuPA Open Proteomics, the official journal of the European Proteomics Association (EuPA).
- Kidney disease is one of the major complications of diabetes and affects approximately one-third of all adult diabetics. Keeping people alive on dialysis costs more than $100,000 per person per year.
- Globally the diabetes epidemic cost health systems $673 billion dollars in 2015.
There is currently no available test for predicting the onset of diabetic kidney disease and Frost & Sullivan suggest PILL is one of only two companies worldwide developing such a test. Results have shown PromarkerD can correctly predict 95% of previously kidney disease-free diabetic patients who go on to develop chronic kidney disease.
Dr Lipscombe said early detection is key to saving lives and money. “PromarkerD means we can accurately predict if someone will get the disease in the next four years so they can take lifestyle and medication action immediately to cut their risks,” he said.
“If we can stem this health crisis tsunami by identifying and treating people before they are symptomatic we are saving lives, as well as billions of dollars in health costs.”
PILL is recognised as a global leader in the field of proteomics.
Publication details
‘Biomarkers Enabling Diabetes and Obesity Management’ published by Frost & Sullivan, March 2, 2017. The report is available via PILL’s website (www.proteomicsinternational.com)
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
